Technology Transfer News

4 June 2020
Membranprotein M: Das häufigste Protein auf der Virushülle.

Supporting the Worlds Scientist in their efforts to against COVID-19

The current Coronavirus pandemic has scientists worldwide collaborating extensively to learn about the virus and develop vaccines as well as therapeutics. Together with scientific and industrial partners including the Paul Scherrer Institute, our spin-off leadXpro has developed a method to provide the research and development community with SARS-CoV-2 M protein. This M protein that is an important part of the virus capsule is a potential target for drugs against the virus. We are happy to invite interested parties wishing to receive protein to contact leadXpro. 


Read more
20 May 2020
Switzerland Innovation launches first call for proposals: Tech4Impact

«Switzerland Innovation Tech4Impact»: Call for Proposals for Groundbreaking Innovation

The current pandemic is also having a severe impact on Switzerland as a business loca-tion. That is why it is particularly important to invest in innovation now. With this in mind, “Switzerland Innovation” Foundation is launching its first major call for proposals to-gether with renowned partners from the Swiss economy. Funding will be provided for in-novation projects that address the most pressing problems of our time.

Read more
30 April 2020
Araris ADC illustration

The PSI Spin-Off Araris Biotech AG is one of the 10 winners of this year’s Venture Leaders Life Science award

As a winner, Araris will take part in the Swiss Biotech Day 2020 and a one-week roadshow to Boston, where Araris along with the other Venture Leaders will be pitching to key US investors and meeting leaders and experts of the biotech and medtech industries. Boston is one of the world’s major life sciences hubs and the ideal springboard for ambitious startups on their way to global expansion.

Read more
7 December 2019
Anaxam Media Conference with Founders, PSI and Kanton

ANAXAM has Officially Launched

Anaxam is a technology transfer center created as a collaboration between PSI, the FHNW, the SNI and the Kanton of Aargau. Created to provide simplified access for industry to the large research facilities at PSI and focused on delivering services to support Advanced Manufacturing, both in the improvement of existing products as well as with manufacturing processes. ANAXAM has Officially Launched today 2019.12.01.

Read more
7 November 2019
Lighting ceremony of the PARK INNOVAARE symbol & groundbreaking of the new innovation campus.

Park Innovaare: Groundbreaking Event

Today, PARK INNOVAARE steps into a new era. Accompanied by more than 200 guests including partners, shareholders, and key politicians, scientists and entrepreneurs, PARK INNOVAARE broke the ground to the construction of its new innovation campus. An investment of 155 CHF million by CPV/CAP Coop Pension Fund has brought this construction project to fruition

Read more
20 August 2019
Antibody Detail

Araris Biotech AG closes seed financing round of CHF 2.5 million

Araris Biotech AG (a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich) announced today the closing of an oversubscribed seed financing round of CHF 2.5 million with participation of Swiss investors Redalpine, Schroder Adveq and VI Partners. The proceeds will be used to develop a pipeline of proprietary antibody-drug conjugates (ADCs)


Read more
1 June 2019
(From left to right) Dr. Benno Rechsteiner, CEO innovAARE AG, Dr. Urs Hofmann, Head of the Department of Economics and Internal Affairs of the Canton of Aargau, Maria Gumann, Chairwoman of the Executive Board of CPV/CAP Pensionskasse Coop, Dr. Remo Lütolf, Chairman of the Board of Directors of innovAARE AG.

Park Innovaare: Financing of new Campus is secured

After an intensive round of negotiations, Park Innovaare concluded an investment agreement with CPV/CAP Pensionskasse Coop for the realization of the new buildings. With this agreement, Park Innovaare has come another step closer to realizing its goal: a state-of-the-art infrastructure of about 38’000 sqm next to the Paul Scherrer Institute PSI that is ideal for industrial R&D projects.

Read more
15 May 2019
Debiopharm Nomination Swiss Biotech Success Story Award

Congratulations to Debiopharm

Debiopharm – a Swiss pharma company that has licensed-in one of PSIs developments -a compound with high potential for cancer diagnosis & therapy has been nominated for the “2019/2020 Swiss Biotech Sucess Stories Awards”

Read more